Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A Plus Avd) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus Abvd In Patients With Previously Untreated Stage Iii Or Iv Hodgkin Lymphoma (Hl): The Phase 3 Echelon-1 Study

Background: Approximately 30% of advanced-stage HL patients have refractory disease or relapse following frontline treatment with ABVD. Brentuximab vedotin is a CD30-directed antibody-drug conjugate approved for classical HL after failure of autologous stem cell transplantation (ASCT) or≥ 2 prior chemotherapy regimens and as consolidation post-ASCT for increased risk HL. We report data from ECHELON-1 (NCT01712490), an unblinded, open-label, randomized, multicenter, phase 3 study comparing A+ AVD with ABVD as frontline therapy in previously untreated advanced HL.Methods: Patients were randomized 1: 1 to receive A+ AVD (brentuximab vedotin 1.2 mg/kg, doxorubicin 25 mg/m 2, vinblastine 6 mg/m 2, dacarbazine 375 mg/m 2) or ABVD (doxorubicin 25 mg/m 2, bleomycin 10 units/m 2, vinblastine 6 mg/m 2, dacarbazine 375 mg/m 2) IV on Days 1 and 15 of up to six 28-day cycles. Patients with a …